NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
10/25/2024
Back to search
Official data from USPTO
OSE IMMUNOTHERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
OSE IMMUNOTHERAPEUTICS
ST13
US500000086942598Class
5, 42, 44
Filing
86942598
Registration
5320086
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
40
Latest update
10/25/2024
Trademark type
Word
Nice classes
5, 42, 44
Filing date
03/16/2016
Registration date
10/31/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/25/2024
Last transaction
10/25/2024
Responsible office
United States Patent and Trademark Office
Status code
705
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
33
Owner location
Nantes, FR
Examiner
SIMCOX,KYLE DUNCAN
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
O. I. (pessoa física)
O. I. (pessoa física)
Orphan Synergy Europe - Pharma
Representatives
Patrick J. Jennings PILLSBURY WINTHROP SHAW PITTMAN, LLP
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products in the nature of chemicals for cancer treatmentoncology and immunotherapy; sanitary preparations for medical purposes; pharmaceutical products for human medicine for cancer treatmentoncology and immunotherapy; Chemical preparations for medical or pharmaceutical purposesfor cancer treatmentoncology and immunotherapy for auto immune diseases and biological tissue grafts or skin grafts; Pharmaceutical productsdiagnostic kits consisting primarily of monoclonal antibodiesbuffersreagents for use in disease testing; Substances for medicinal usesynthetic peptides for cancer treatmentoncology and immunotherapyadjuvants for medical purposesstem cells for medical purposes; Vaccines for treating cancer; vaccines; Substances for medicinal useserums for cancer treatmentoncology and immunotherapymonoclonal antibodies for cancersauto immune diseases and biological tissue grafts or skin grafts; Pharmaceutical productstargeted therapies for cancersauto immune diseases and biological tissue grafts or skin grafts
Class 42
Scientific and technological servicesresearch and design services in the fields of cancer treatmentoncologyimmunotherapy; design and development of software and databases; medical research; biological and biotechnology research; pharmaceutical research; conducting clinical studies for others
Class 44
Medical services
Publications
History of USPTO decisions and trademark events.
40 publications found
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
10/25/2024
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
10/25/2024
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
10/23/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/23/2024
E815
TEAS SECTION 8 & 15 RECEIVED
04/30/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
10/31/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
10/31/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/15/2017
PUBO
PUBLISHED FOR OPPOSITION
08/15/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/26/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/06/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/08/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/08/2017
ALIE
ASSIGNED TO LIE
06/02/2017
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
05/08/2017
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
05/08/2017
GNFR
FINAL REFUSAL E-MAILED
05/08/2017
CNFR
FINAL REFUSAL WRITTEN
05/08/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/10/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/10/2017
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
04/10/2017
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
11/25/2016
GNSL
LETTER OF SUSPENSION E-MAILED
11/25/2016
CNSL
SUSPENSION LETTER WRITTEN
11/25/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/24/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/24/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/24/2016
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/20/2016
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/20/2016
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
08/03/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/06/2016
GNRT
NON-FINAL ACTION E-MAILED
07/06/2016
CNRT
NON-FINAL ACTION WRITTEN
07/06/2016
DOCK
ASSIGNED TO EXAMINER
06/27/2016
TAEA
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
03/23/2016
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
03/23/2016
MPMK
NOTICE OF PSEUDO MARK E-MAILED
03/22/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/21/2016
NWAP
NEW APPLICATION ENTERED
03/19/2016
Continuous trademark protection
Get notified about every new filing that threatens OSE IMMUNOTHERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.